Loading video...

Video Failed to Load

Go Home

Introducing #mBER: our open-source AI library for de novo, format-aware antibody design. Paired with in vivo multiplexed screening, mBER forms Manifold Bio's direct-to-vivo drug discovery platform, bridging the gap between AI-guided design and biological translation.

15,504 views • 9 months ago •via X (Twitter)

0 Comments

No comments available

Comments from the original post will appear here

Related Videos

Excited to launch "Novix"🚀, our PhD-level AI-Scientist designed for autonomous scientific discovery. Novix revolutionizes research workflows through comprehensive capabilities spanning: deep research, innovative ideation, intelligent coding, advanced data analysis, automated experimentation, and paper writing. 🌐 Platform Access: 👉 Open-Source Foundation: 🚀 Accelerated Scientific Discovery Pipeline: From concept to publication-ready research with unprecedented efficiency ✨ Core Capabilities: - 🧠 Research Co-Pilot Intelligence: AI-powered ideation and hypothesis generation that collaborates with your research intuition - ⚙️ Autonomous Algorithm Innovation: End-to-end design, implementation, and validation of novel computational approaches - 📊 Intelligent Data Orchestration: Advanced analytics with automated insights discovery and compelling visualizations - 🔬 Scientific Reproducibility Engine: Automated verification and replication of research methodologies and findings - 📚 AI-Powered Deep Survey: Comprehensive literature synthesis and gap analysis across scientific domains We're building an AGI Level 4 innovation engine that empowers researchers, developers, and businesses to achieve breakthrough results in scientific innovation and discovery. From our open-source foundation to this production-ready platform, Novix represents a paradigm shift in how we reshape scientific discovery. 🎁 Launch Benefits - 🚪 Barrier-Free Access: Simply register and start exploring - 💰 Welcome Bonus: New users receive $5 in credits to experience the platform's full potential - 🎯 Enhanced Experience: Complete our user feedback survey to unlock a $20 Pro account with complete feature access We deeply understand the challenges of research work and genuinely hope Novix can serve as your trusted research companion. Join us in this exciting journey of AI-powered scientific discovery and help shape the future of research innovation!

Chao Huang

16,854 views • 10 months ago

Today, we expand zero-shot drug design beyond binding to the design of multifunctional medicines, the intracellular proteome, and state-of-the-art atomic precision with our model, JAM-2. In a new report (below), we show: 1. The first drug-grade, fully computationally designed multispecific antibodies against five peptide-MHCs: Routine picomolar T-cell activation/cell-killing EC50s, >100-fold selectivity, and drug-like developability 2. The first fully generatively designed, drug-grade dual-variant KRAS G12 multispecifics: They recruit primary T-cells from human donors to kill G12V and G12C presenting cells at pM to single-digit-nM potency, completely sparing wild-type. 3. Atomic accuracy, from sequence alone: Angstrom-level agreement between Cryo-EM and JAM-2 de novo designs, requiring only target sequences (not structure) as input. 4. Unrivaled speed with an AI-native in-house wet lab: Designed, built, and tested five programs in one parallelized campaign, end-to-end in-house in ~6 weeks. 5. A higher validation bar for AI-generated drug candidates: In a field increasingly rife with hype and uneven standards of proof, we provide the highest quality public wet-lab validation of AI-designed antibodies to date. We share experimental methods in full, and invite folks to adopt and build on these standards. Truly individualized therapies will be the most important contribution of AI in drug design. These advances help accelerate this future.

Nabla Bio

175,423 views • 22 days ago